« Back
Home /
Lapatinib

Lapatinib

Item no.	TMO-T0078-1g
Manufacturer	TargetMol
CASRN	231277-92-2
Amount	1 g
Quantity options	1000 mg 100 mg 1 mL x 10 mM (in DMSO) 10 mg 1 g 1 mL 200 mg 25 mg 500 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.89%
Citations	Wainberg ZA, et al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res. 2010 Mar 1;16(5):1509-19.
Smiles	N(C=1C2=C(C=CC(=C2)C=3OC(CNCCS(C)(=O)=O)=CC3)N=CN1)C4=CC(Cl)=C(OCC5=CC(F)=CC=C5)C=C4
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	GSK572016,GW572016
Shipping Condition	Cool pack
Available
Manufacturer - Targets	EGFR\|\|\|Autophagy\|\|\|Ferroptosis
Shipping Temperature	Cool pack
Storage Conditions	-20
Molecular Weight	581.06
Description	Lapatinib (GW572016) is an inhibitor of ErbB2 and EGFR (IC50=9.2/10.8 nM) with oral activity. Lapatinib has antitumor activity and can be used to treat advanced or metastatic breast cancer with HER2 overexpression.
Pathways	Angiogenesis\|\|\|Tyrosine Kinase/Adaptors\|\|\|Autophagy\|\|\|JAK/STAT signaling\|\|\|Apoptosis

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

TMO-T0078-1g-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 1 g

available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question